Abstract:Background: Success of T cell immunotherapy hinges on the tumor microenvironment (TME), and abnormal tumor vasculature is a hallmark of most solid tumors and associated with immune evasion. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and cytolytic activity of T cells in solid tumors. Normalization of tumor vasculature using vascular endothelial growth factor (VEGF) blockades could improve efficacy of BsAb-based T cell immunotherapy. Methods: Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit. Tumor infiltrating lymphocytes (TILs) were evaluated using flow cytometry and by bioluminescence; both TILs and tumor vasculature were studied using immunohistochemistry. Results: VEGF expression on cancer cell lines increased with seeding density in vitro. BVZ significantly reduced serum VEGF levels in mice. BVZ or DC101 increased high endothelial venules (HEVs) in the TME and substantially enhanced (2.1-8.1 fold) BsAb-driven T cell infiltration into neuroblastoma and osteosarcoma xenografts, which was preferential for CD8(+) TILs versus CD4(+) TILs, leading to superior antitumor effects in multiple CDX and PDX tumor models without added toxicities. Conclusions: VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapies.

Antibody-directed Targeting of Tumor Vasculature

Study on Hypovascular Tumor' S Treatment with Targeted Mierobubbles Combined with Ultrasonic Abrupted Destroy

Advancement on Targeting Therapy of Tumor Vessels

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Research Progress on Tumor-Targeting Immunoconjugate

in vitro Model for Targeting Tumor Vasculature Using Immunoliposome

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

[The Effect of Antibody Against Vascular Endothelial Growth Factor (VEGF) on Tumor Metastasis].

Targeting Tumor Cells with Antibodies Enhances Anti-Tumor Immunity

The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis.

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

Recent advances of nanotechnology-based tumor vessel-targeting strategies

Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy

Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors*

Integrin targeted delivery of radiotherapeutics.

Integrin αvβ3-targeted cancer therapy

The Effect of Anti-Vegf Antiserum on the Progression of Bladder Cancer in Mouse Model

[Preparation of functional antibodies targeting tumor endothelia for the treatment of hepatic carcinoma].

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells

Progress in Anti-Angiogenesis Targeted Drugs